- Home
- CHMI vs AVTX Comparison
CHMI vs AVTX Comparison
Compare CHMI & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHMI
- AVTX
- Stock Information
- Founded
- CHMI 2012
- AVTX 2011
- Country
- CHMI United States
- AVTX United States
- Employees
- CHMI N/A
- AVTX N/A
- Industry
- CHMI Real Estate Investment Trusts
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- CHMI Real Estate
- AVTX Health Care
- Exchange
- CHMI Nasdaq
- AVTX Nasdaq
- Market Cap
- CHMI 92.0M
- AVTX 77.7M
- IPO Year
- CHMI 2013
- AVTX 2015
- Fundamental
- Price
- CHMI $3.00
- AVTX $6.75
- Analyst Decision
- CHMI Buy
- AVTX Strong Buy
- Analyst Count
- CHMI 2
- AVTX 4
- Target Price
- CHMI $5.00
- AVTX $33.00
- AVG Volume (30 Days)
- CHMI 473.0K
- AVTX 137.5K
- Earning Date
- CHMI 03-06-2025
- AVTX 11-07-2024
- Dividend Yield
- CHMI 20.00%
- AVTX N/A
- EPS Growth
- CHMI N/A
- AVTX N/A
- EPS
- CHMI N/A
- AVTX N/A
- Revenue
- CHMI N/A
- AVTX $820,000.00
- Revenue This Year
- CHMI N/A
- AVTX N/A
- Revenue Next Year
- CHMI $27.78
- AVTX N/A
- P/E Ratio
- CHMI N/A
- AVTX N/A
- Revenue Growth
- CHMI N/A
- AVTX N/A
- 52 Week Low
- CHMI $2.50
- AVTX $4.01
- 52 Week High
- CHMI $3.99
- AVTX $34.46
- Technical
- Relative Strength Index (RSI)
- CHMI 65.37
- AVTX 32.78
- Support Level
- CHMI $2.67
- AVTX $5.99
- Resistance Level
- CHMI $2.83
- AVTX $7.17
- Average True Range (ATR)
- CHMI 0.11
- AVTX 0.91
- MACD
- CHMI 0.04
- AVTX -0.05
- Stochastic Oscillator
- CHMI 100.00
- AVTX 23.17
About CHMI Cherry Hill Mortgage Investment Corporation
Cherry Hill Mortgage Investment Corp operates as a real estate investment trust in the United States. It invests in residential mortgage assets to generate current yields and risk-adjusted total returns for its stockholders over the long term, primarily through dividend distributions and secondarily through capital appreciation. The company's reportable segments include investments in Residential mortgage-backed securities (RMBS), Investments in Servicing Related Assets, and All Others. It generates maximum revenue from the RMBS segment in the form of Interest income earned for servicing mortgage loans.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).